Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CPS1 | P31327 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122251 | 0.88 | GHSR (0.34) | ALDH1A1GHSRTSHRCHRM1CHRM2 | |
| SCHEMBL1709698 | 0.87 | DPP7 (0.35) | DPP7HRH3ALDH1A1MAPTGHSR | |
| SCHEMBL10122242 | 0.86 | AGTR2 (0.33) | ALDH1A1GHSRTSHRCHRM1CHRM2 | |
| SCHEMBL10121857 | 0.86 | GHSR (0.44) | DPP7HRH3ALDH1A1MAPTGHSR | |
| SCHEMBL10122095 | 0.85 | GHSR (0.45) | DPP7HRH3ALDH1A1MAPTGHSR | |
| SCHEMBL1709638 | 0.85 | GHSR (0.40) | DPP7HRH3ALDH1A1MAPTGHSR | |
| SCHEMBL1709693 | 0.85 | GHSR (0.35) | ALDH1A1GHSRTSHRBCHEACHE | |
| SCHEMBL1709573 | 0.76 | GHSR (0.44) | DPP7HRH3ALDH1A1MAPTGHSR | |
| SCHEMBL10121858 | 0.75 | GHSR (0.46) | ALDH1A1MAPTGHSRTSHRBCHE | |
| SCHEMBL1709651 | 0.75 | GHSR (0.56) | DPP7HRH3ALDH1A1MAPTGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | DPP7 1048/4885HRH3 706/4885ALDH1A1 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.